Modulation of the poly (ADP-ribose) polymerase inhibitor response and DNA recombination in breast cancer cells by drugs affecting endogenous wild-type p53

Fluorescence-based recombination assay for sensitive and specific detection of genotoxic carcinogens in human cells

(2014) Ivanildce C. Ireno et al.   ARCHIVES OF TOXICOLOGY

siRNA screening identifies differences in the Fanconi anemia pathway in BALB/c-Trp53+/− with susceptibility versus C57BL/6-Trp53+/− mice with resistance to mammary tumors

(2013) M Böhringer et al.   ONCOGENE

The diverse roles and clinical relevance of PARPs in DNA damage repair: Current state of the art

(2012) Mike De Vos et al.   BIOCHEMICAL PHARMACOLOGY

Trapping of PARP1 and PARP2 by Clinical PARP Inhibitors

(2012) J. Murai et al.   CANCER RESEARCH

Mre11-Dependent Degradation of Stalled DNA Replication Forks Is Prevented by BRCA2 and PARP1

(2012) S. Ying et al.   CANCER RESEARCH

Clinicopathological Features of Homologous Recombination-Deficient Epithelial Ovarian Cancers: Sensitivity to PARP Inhibitors, Platinum, and Survival

(2012) A. Mukhopadhyay et al.   CANCER RESEARCH

A killer promoting survival: p53 as a selective means to avoid side effects of chemotherapy

(2012) Dominique Kranz et al.   CELL CYCLE

Evaluation of candidate biomarkers to predict cancer cell sensitivity or resistance to PARP-1 inhibitor treatment

(2012) Lenka Oplustilova et al.   CELL CYCLE

Molecular Pathways: Targeting PARP in Cancer Treatment

(2012) K. Do et al.   CLINICAL CANCER RESEARCH

The Structure-Based Design of Mdm2/Mdmx-p53 Inhibitors Gets Serious

(2011) Grzegorz M. Popowicz et al.   ANGEWANDTE CHEMIE-INTERNATIONAL EDITION

Resistance and gain-of-resistance phenotypes in cancers harboring wild-type p53

(2011) Michelle Martinez-Rivera et al.   BIOCHEMICAL PHARMACOLOGY

High Nuclear Poly(Adenosine Diphosphate-Ribose) Polymerase Expression Is Predictive forBRCA1- andBRCA2-Deficient Breast Cancer

(2011) Luka Ozretić et al.   JOURNAL OF CLINICAL ONCOLOGY

Inhibition of p53 expression by peptide-conjugated phosphorodiamidate morpholino oligomers sensitizes human cancer cells to chemotherapeutic drugs

(2011) W Ma et al.   ONCOGENE

Dissection of the sequence-specific DNA binding and exonuclease activities reveals a superactive yet apoptotically impaired mutant p53 protein

(2010) Jinwoo Ahn et al.   CELL CYCLE

A Distinctive DNA Damage Response in Human Hematopoietic Stem Cells Reveals an Apoptosis-Independent Role for p53 in Self-Renewal

(2010) Michael Milyavsky et al.   Cell Stem Cell

Poly(ADP)-Ribose Polymerase Inhibition: Frequent Durable Responses inBRCACarrier Ovarian Cancer Correlating With Platinum-Free Interval

(2010) Peter C. Fong et al.   JOURNAL OF CLINICAL ONCOLOGY

The C terminus of p53 binds the N-terminal domain of MDM2

(2010) Masha V Poyurovsky et al.   NATURE STRUCTURAL & MOLECULAR BIOLOGY

Ablation of Key Oncogenic Pathways by RITA-Reactivated p53 Is Required for Efficient Apoptosis

(2009) Vera V. Grinkevich et al.   CANCER CELL

DNA double-strand break repair activities in mammary epithelial cells--influence of endogenous p53 variants

(2009) M. Keimling et al.   CARCINOGENESIS

Pifithrin-α protects against DNA damage-induced apoptosis downstream of mitochondria independent of p53

(2009) D Sohn et al.   CELL DEATH AND DIFFERENTIATION

Dissecting the role of p53 phosphorylation in homologous recombination provides new clues for gain-of-function mutants

(2008) A. Restle et al.   NUCLEIC ACIDS RESEARCH